secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0002019410-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%
--------------------------------------------------------------------------------

- Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.
- Full-year 2025 revenue ~$800M (+94% YoY); Pharma R&D services ~$45M.
- Q4 clinical therapy selection cases ~52,700 (+20%); full-year ~199,300 (+22%).
- Cash, equivalents and marketable securities ~$802M as of Dec 31, 2025, up ~$43M from Sep 30, 2025.
- Company presenting at 44th J.P. Morgan Healthcare Conference today; complete earnings call expected in late Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/0002019410-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai-20260112.htm
  HTML page:      https://secwatch.observer/filing/0002019410-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer